Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis (Pro-Muco)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by University Hospital, Tours.
Recruitment status was  Recruiting
Information provided by:
University Hospital, Tours Identifier:
First received: September 10, 2008
Last updated: November 13, 2008
Last verified: November 2008

September 10, 2008
November 13, 2008
January 2008
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00750932 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis
Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-Inflammatory Therapies

The purpose of the proposed project is to characterize the neutrophile proteases which participate in the chronic inflammatory phenomenon associated with the cystic fibrosis and which are responsible for the degradation of the lung tissue.

The respiratory failure which results from it is one of main causes of the fatal evolution of this pathology but the anti-inflammatory therapies based on the use of antiproteases targeting specifically the soluble elastase did not end, until now, in the hoped results.

The identification of the other noxious targets is a crucial element to give new orientations to the anti-inflammatory strategies based on the administration of antiproteases which remain a promising way.

Not Provided
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Whole blood Sputum
Non-Probability Sample
Adults and children with cystic fibrosis
Cystic Fibrosis
Not Provided
  • T
  • M
    Minor with cystic fibrosis
  • A
    Adult with cystic fibrosis
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • Man /woman older than 18 years (for adult and group)
  • Child aged 6 to 18 years (for child group)
  • Suffering from cystic fibrosis in stable condition, ie not having presented thrust acute attack of the broncho-pulmonary or hospitalization for treatment of his illness during the previous 2 weeks

Exclusion Criteria:

  • colonized by Burkholderia cepacia ou Stenotrophomonas maltophilia
  • non smoker (control group)
  • Without history or respiratory respiratory disease known (control group)
  • Antibiotic treatment and / or anti-inflammatory drug (NSAID or corticosteroids) in the 2 weeks prior to the inclusion in the study (control group)
6 Years and older   (Child, Adult, Senior)
Contact: Patrice DIOT, PHD +33247473787
Contact: Pascaline RAMEAU +33247474664
AOHP07-PD Pro-Muco, DGS2007-0295, N° ID RCB:2007-A00511-52, CPP: 2007-R17
Not Provided
Not Provided
University Hospital, Tours
University Hospital, Tours
Not Provided
Principal Investigator: Patrice DIOT, PHD Tours Hospital
University Hospital, Tours
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP